Nicholas John Van As

Royal Marsden NHS Foundation Trust

Papers

1

Total Citations

31

H-Index

1

About

Nicholas John Van As is a leading clinical academic and radiation oncologist whose research focuses on advancing the treatment of localised prostate cancer through high-precision radiotherapy. His major contribution lies in challenging the therapeutic equipoise between surgery and radiotherapy, most notably as the chief investigator of the landmark PACE-A trial. This international phase 3 randomised controlled trial, published in 2023, directly compared stereotactic body radiotherapy (SBRT) to radical prostatectomy, with its primary endpoint analysis accumulating over 30 citations. The study is pivotal for demonstrating that SBRT offers comparable cancer control with a distinct quality-of-life profile, providing patients with a less invasive alternative to surgery. Van As’s work has been instrumental in shifting clinical practice towards more tailored, evidence-based decision-making in early-stage prostate cancer. His research not only validates the efficacy of ultra-hypofractionated radiotherapy but also empowers patients and clinicians with robust data on treatment trade-offs, cementing his reputation as a key figure in modern uro-oncology.

Research Focus

Key Achievements

1
H-Index
1
Papers
31
Total Citations
31
Avg Citations/Paper
🏆 Most Cited Paper
PACE-A: An international phase 3 randomised controlled trial (RCT) comparing stereotactic body radiotherapy (SBRT) to surgery for localised prostate cancer (LPCa)—Primary endpoint analysis.
31 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 18
🏛 Institutions: Royal Marsden NHS Foundation Trust

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago